Therapeutic challenges at the preclinical level for targeted drug development forOpisthorchis viverrini-associated cholangiocarcinoma / Watcharin Loilome, Hasaya Dokduang, Manida Suksawat, Sureerat Padthaisong
ABSTRACT Introduction Cholangiocarcinoma (CCA) is a malignant tumor of bile duct epithelium with the highest incidence found in Thailand. Some patients are considered suitable for adjuvant therapy and surgical resection is currently the curative treatment for CCA patients. Tumor recurrence is still a hurdle after treatment; hence, finding novel therapeutic strategies to combat CCA is necessary for improving outcome for patients. Areas covered We discuss targeted therapies and other novel treatment approaches which include protein kinase inhibitors, natural products, amino acid transporter-based inhibitors, immunotherapy, and drug repurposing. We also examine the challenges of tumor heterogeneity, cancer stem cells (CSCs), the tumor microenvironment, exosomes, multiomics studies, and the potential of precision medicine. Expert opinion Because CCA is difficult to diagnose at the early stage, the traditional treatment approaches are not effective for many patients and most tumors recur. Consequently, researchers are exploring multi-aspect molecular carcinogenesis to uncover molecular targets for further development of novel targeted drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 30(2021), 9, Seite 985- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loilome, Watcharin [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (22 p) |
|---|
| doi: |
10.1080/13543784.2021.1955102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL009139095 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009139095 | ||
| 003 | DE-627 | ||
| 005 | 20230621210127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220511s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2021.1955102 |2 doi | |
| 035 | |a (DE-627)KFL009139095 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/13543784.2021.1955102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Loilome, Watcharin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic challenges at the preclinical level for targeted drug development forOpisthorchis viverrini-associated cholangiocarcinoma |c Watcharin Loilome, Hasaya Dokduang, Manida Suksawat, Sureerat Padthaisong |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (22 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction Cholangiocarcinoma (CCA) is a malignant tumor of bile duct epithelium with the highest incidence found in Thailand. Some patients are considered suitable for adjuvant therapy and surgical resection is currently the curative treatment for CCA patients. Tumor recurrence is still a hurdle after treatment; hence, finding novel therapeutic strategies to combat CCA is necessary for improving outcome for patients. Areas covered We discuss targeted therapies and other novel treatment approaches which include protein kinase inhibitors, natural products, amino acid transporter-based inhibitors, immunotherapy, and drug repurposing. We also examine the challenges of tumor heterogeneity, cancer stem cells (CSCs), the tumor microenvironment, exosomes, multiomics studies, and the potential of precision medicine. Expert opinion Because CCA is difficult to diagnose at the early stage, the traditional treatment approaches are not effective for many patients and most tumors recur. Consequently, researchers are exploring multi-aspect molecular carcinogenesis to uncover molecular targets for further development of novel targeted drugs | ||
| 700 | 1 | |a Dokduang, Hasaya |e verfasserin |4 aut | |
| 700 | 1 | |a Suksawat, Manida |e verfasserin |4 aut | |
| 700 | 1 | |a Padthaisong, Sureerat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 1994 |g 30(2021), 9, Seite 985- |h Online-Ressource |w (DE-627)KFL000006041 |w (DE-600)2030114-5 |w (DE-576)302969314 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2021 |g number:9 |g pages:985- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/13543784.2021.1955102 |m X:KFL |x Resolving-System |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2021 |e 9 |h 985- | ||